Intel stock extends gains after report of possible U.S. government stake
Investing.com -- Tivic Health Systems, Inc. (NASDAQ:TIVC) stock surged 55% on Thursday after the company announced progress in discussions with key U.S. government agencies regarding the potential use of its Entolimod product as a radiation countermeasure for military personnel.
The therapeutics company participated in the 2025 Military Health System Research Symposium (MHSRS) held August 4-7 in Kissimmee, Florida, where company executives met with representatives from the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI), and the Medical CBRN Defense Consortium (MCDC).
Michael Handley, Tivic’s President of Biopharma and Chief Operating Officer, engaged with these agencies to explore potential pathways for deploying Entolimod as a military countermeasure against radiation exposure. The discussions focused on how the company’s lead clinical product candidate could potentially protect military personnel exposed to radiation in the field.
"It was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation," said Handley.
The MHSRS is the Department of Defense’s premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation supporting warfighter health and readiness. The symposium provides companies like Tivic direct access to organizations seeking military partnerships and connects them with key funding organizations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.